Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U87 CAR-T in advanced head and neck tumors
NCT06614686Phase 1Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of U87 autologous CAR T-cell in head and neck cancer (HNC) and nasopharyngeal carcinoma (NPC), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Incidence of Adverse events after U87 CAR-T cells infusion at 28 days. Started Sep 2024; status: recruiting.
02
Drugs
U87 autologous CAR T-cell
03
Conditions
head and neck cancer (HNC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06614686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614686.